Watson Pharmaceuticals Inc is on track to announce a M&A deal to buy Actavis for around $6 billion by the end of April, creating one of the world's biggest producers of generic drugs, sources familiar with the matter said on Wednesday.
The remaining part of this article is Premium content – see below for access options.
CP Insight – Premium content section
This is a premium content section and requires a paid subscription to access.
Read: more on dealtalk in pharma, biotech, life science partnering deal news, insights and glossary
View: Top 50 pharma – overview of top 50 pharmaceutical companies by revenue – partnering activity, deal news, partnering dealtalk
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity